If she is that familiar with PAR management, given all the information provided, I think PAR management will work out who she is in a flash.
A miracle drug - maybe not. A potential blockbuster drug - most certainly in my opinion. As for patent protection issues, and legalities aside, from what much respected Mozzarc has suggested in the past, trying to replicate our iPPS would be incredibly onerous and would take many years with no guarantee of success. I'm not worried at this stage.
The 'very poor management' (and I know we've all had our issues with them) have brought a drug to P3 with Fast Track designation and potential disease modifying status. - She's admitted it has been effective for herself, her husband and some of her customers, and obviously it is her preferred treatment for her condition, but she doesn't like management. I suspect there is more to this than she is telling us. It doesn't add up for me.
The pharmaceutical industry is not going to turn their back on potentially massively increased profits because they don't like PAR management. They will find a way to work with them. I think management are fine, but they have their eyes on the end game, the long term, whereas punters like me want a great result yesterday.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)